Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 19/20 | 0.52 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6778530 | 1.00 | PARP1 (0.52) | PARP1PBKPARP2 | |
| SCHEMBL6780404 | 0.90 | PBK (0.46) | PARP1PBKPARP2 | |
| SCHEMBL6782750 | 0.90 | PARP1 (0.52) | PARP1PARP2 | |
| SCHEMBL5072053 | 0.88 | PARP1 (0.54) | PARP1PARP2 | |
| SCHEMBL6786430 | 0.87 | PARP1 (0.50) | PARP1PARP2 | |
| SCHEMBL6783911 | 0.87 | PARP1 (0.50) | PARP1PARP2 | |
| SCHEMBL6786783 | 0.87 | PARP1 (0.50) | PARP1PARP2 | |
| SCHEMBL5619953 | 0.87 | PARP1 (0.65) | PARP1PARP2 | |
| SCHEMBL6783310 | 0.86 | PBK (0.52) | PARP1PBKPARP2 | |
| SCHEMBL5077310 | 0.86 | PBK (0.49) | PARP1PBKPARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008154129-A1 | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING, REDUCING, AMELIORATING, ALLEVIATING, OR PREVENTING DRY EYE | BAUSCH & LOMB INCORPORATED (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | BAUSCH & LOMB INCORPORATED | 2008-12-11 | — | — | US | claimed |
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | BAUSCH & LOMB INCORPORATED | 2008-12-11 | — | — | US | disclosed |
| US-6737421-B1 | 4-CARBOXYAMIDO SUBSTITUTED; NEURODEGENERATIVE DISEASES; NEURONAL DAMAGE | ABBOTT GMBH & CO. KG (DE) | 2004-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305994-A1 | Pharmaceutical Compositions and Method for Treating, Reducing, Ameliorating, Alleviating, or Preventing Dry Eye | PARP1, PARP2, PARP12 | PARP1 1/4885PBK 4602/4885PARP2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.